BioPharma Resources

Drug Trial Radar · NCT07217301

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Nov 26, 2025

Primary completion

Nov 1, 2028

Study completion Dec 1, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
First posted
Oct 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. NSCLC can be divided into types based on where cancer starts. Some NSCLC starts in the cells that line the larger airways near the center of the lungs. This is called squamous NSCLC. Other NSCLC often starts in the outer parts of the lungs, in cells that make mucus. This is called nonsquamous NSCLC. This study focuses on squamous and nonsquamous NSCLC in later stages (advanced). This means that the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery (unresectable). People with unresectable, advanced or metastatic squamous or nonsquamous NSCLC often get treatment with immunotherapy and/or platinum-based chemotherapy (such as cisplatin or carboplatin). Immunotherapy helps the body's germ-fighting (immune) system fight cancer. Chemotherapy kills cancer cells or slows their growth. Over time, these treatments may stop working and the cancer can get worse. Researchers are looking for ways to make immunotherapy work better. One approach is to help the immune system recognize cancer more easily by activating certain cells, called T cells, to attack and kill the tumor cells. TAK-928 is designed to attach to T cells in the tumor. This may make the T-cells more active and increase their number. This may help the body fight the cancer and destroy tumor cells. The main aim of this study is to learn how well TAK-928 works and compares with the usual treatment (also called standard of care), docetaxel, in adults with unresectable, advanced or metastatic squamous or nonsquamous NSCLC. Another aim is to learn how safe TAK-928 is in adults with NSCLC. The participants can be treated for up to 2 years (24 months). Total treatment duration can vary depending on how a participant responds, side effects, or other reasons. Researchers will check a participant's condition until the treatment is ended. During the study, participants will visit the study clinic several times.

Conditions

  • IO Resistant Squamous and Nonsquamous NSCLC

Interventions

  • TAK-928Drug

    TAK-928 will be administered by IV infusion.

  • Control ArmDrug

    Comparator product will be administered by IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Squamous NSCLC Part: Confirmed Objective Response Rate (cORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1Time frame: Up to 26 months
  2. Squamous and Nonsquamous NSCLC Part: Overall Survival (OS)Time frame: Up to 26 months
  3. SRI Part: Percentage of Participants with Dose-limiting Toxicities (DLTs)Time frame: Up to 28 days after first dose (Day 1)
  4. SRI Part: Percentage of Participants With Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Immune-Related Adverse Events (irAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation and DeathsTime frame: From screening up to 26 months

Locations

50 sites in 3 countries. Site status is shown where the registry gives one.

  • St. Bernards Healthcare

    Jonesboro, Arkansas · Recruiting

  • Apex Research

    Fair Oaks, California · Recruiting

  • Memorial Care

    Fountain Valley, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • Translation Research in Oncology- US, INC (TRIO-US)

    Torrance, California · Recruiting

  • MedStar Georgetown Cancer Institute-Oncology Research

    Washington D.C., District of Columbia · Recruiting

  • D & H Cancer Research Center

    Margate, Florida · Recruiting

  • BRCR Global

    Tamarac, Florida · Recruiting

  • Oncology Hematology Associates

    Springfield, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • The University of Texas M.D Anderson Cancer Center (MDACC)

    Houston, Texas · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • The Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The Fourth Hospital of Hebei University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Withdrawn

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'An Jiaotong University

    Xi'an, Shannxi, China · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.